Simpler Grants.gov #PAR-25-070

NIH Grant for Mechanistic Research on Incretin Mimetics and Cancer Risk

This opportunity from the National Institutes of Health (NIH) seeks grant applications for research on how incretin mimetics influence cancer risk mechanisms. - Government Buyer: - National Institutes of Health (NIH) - Products/Services Requested: - Mechanistic research on incretin mimetics (GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) and their impact on cancer risk - Focus on preclinical and patient-based studies - No clinical trials permitted (R21 Clinical Trial Not Allowed) - No specific products, part numbers, or purchase quantities requested - Unique/Notable Requirements: - Emphasis on understanding biological mechanisms, not short-term outcomes like weight loss or diabetes - Open to a wide range of applicants: nonprofits, government entities, businesses, educational institutions, and others - No cost sharing or matching required - Assistance Listing 93.393 (Cancer Cause and Prevention Research) - No OEMs or vendors are specified, as this is a research grant opportunity, not a product or service procurement.

Description

This funding announcement aims to support preclinical and patient-based studies investigating the mechanisms by which incretin mimetics (including GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) influence cancer risk. The focus is on understanding how these agents affect cancer risk rather than short-term outcomes like weight loss and diabetes. Current data suggest these agents may increase the risk of some obesity-related cancers while decreasing the risk of others. The announcement seeks to attract scientists to explore these dynamic changes and mechanisms.

View original listing